Optibiotix Health Share Discussion Threads

[jestercat2] 06/10/2017 13:26

Have trades really dried up or has my feed failed?

[fathenry] 06/10/2017 13:03

zzzzzzzzzzzzz, nufin doin borin, back to me chips

[shrewdmole] 06/10/2017 12:45

Elrico

I feel understandably chastised!

S

[elrico] 06/10/2017 12:31

From SOH

Their is more to come on this area of sweeteners/sugars and the microbiome in general. As we now have products on the market and build an online consumer presence we are engaging with PR groups to promote the microbiome and our products. We have been very successful in the last few years with a number of article sin the Times, Mail,Telegraph, Nature etc but hope to expand this coverage as we build market understanding and awareness of the benefits of our products. We see the microbiome as the future of healthcare and ourselves as very much leading the use of microbiome based products in healthcare.

We have just got our OptiBiotic principle onto Wkilpedia. Currently its part of a listing on synbiotics see

we anticipate this becoming a listing in its own right in a few months. This is just a small piece in building up the understanding and market awareness of our science and the benefits it brings to healthcare.

Feel free to share.

[jestercat2] 06/10/2017 12:05

Nice to see your 44K buy go through Shrewdmole.

[elrico] 06/10/2017 11:35

Shrewdmole - Pay attention, I have covered this valuation topic before. :)


There are multiple applications, each have multiple products, multiple partners and multiple territories, thus multiple revenue streams ranging from licensing, profit share, distribution, sales and manufacturing. If I reiterate what SOH has said; "Our strategy is to build multiple partnerships and the £3-6m is based on approx 10 national partnerships per application areas each delivering £300-£500K per year of existing products which comes from our discussions at Vitafoods, It DOES NOT INCLUDE RETAIL PARTNERSHIPS which in themselves can be worth £5-6m, OR OTHER APPLICATION AREAS such as dairy, snack bars etc or partnerships with global corporates as these are more difficult to forecast both in terms of deal structure and timescale." This should give us confidence of the potential size of revenues per application and indication of the size of company.

Revenues in of £20-30m UNDER current industry standards would value Optiscreen division in the region of £200-300m. Perhaps this seems wishful. However, ProBi’s valuation of £500m at today's value on £25m sales in 2015 accounts. Valuation on Probiotic market on 10-20x industry. OPTI as group is far more divers than Probi. The only advantage Probi has over OPTI is its established market presence, but under SACCO and Nutrillnea, that is already making headway.

[dorset64] 06/10/2017 11:25

Devonlad6 Oct '17 - 08:05 - 27788 of 27799 0 0
Do you like it Dorset, buy and hold for a good few years might make you a lot, not that you need it mind!
==========================================

Lol DL, like you I'm married, so I need every penny I can get :)

The story looks good here especially as the term story is replaced by fact, as in they are being used today to good effect. Therefore this will, imo, only increase over the coming years both in size & profits of the company complete with hand-in-hand wiht the share price.

I bought in to both you mentioned DL so thanks for that but only a small intro in the 'other' one, though a slightly bigger one here. Did you buy into ARS?

[1bokke] 06/10/2017 11:12

Thanks Moormoney, on the plus side however whilst in hospital I turned bright yellow and my young daughter now thinks I'm a secret minion and has told all her classmates that!! It's not quite a superhero but I'll take what I can get!

[shrewdmole] 06/10/2017 10:57

Guys what multiplier would one apply for a high growth stock?

I'm thinking 20 to 25 if it's high growth?

I'm just trying (albeit it's pure guesswork) to get a handle on a potential valuation of Opti in 12,24,36 months time.

The problem I'm finding is the revenues come from so many different products, agreements and commissions it's nigh on impossible to cover all the potential revenue streams.

As soon as we get thoughts on one deal there's another Jv or agreement announced.

The bened deal for example - could be huge taking a proven strain with extg sales to launch in Europe and the US. But what figure do you put on it?

The dairy market and cereal ingredients could be selling the ingredient to go in pretty much any and all products on shelves in supermarkets.

It's mind boggling.

I'm actually going to give up trying to put a guesstimate on revenue and valuation.

Will leave that to the researchers and brokers.

S

[moormoney] 06/10/2017 10:56

1bokke not a nice way to lose weight! I hope you’re better soon and Opti rise cheers you up.

[joyjoy13] 06/10/2017 10:50

Someuwin
Interesting article,fully understand the implications, we're getting this sort of article popping up a lot of late, uplifting to think there's going to be help, proper help in the future, for folk suffering from depression...
thanks for posting.

[shrewdmole] 06/10/2017 10:40

They are soaking up a lot of sells and looking very strong.
Got to be a buy order being filled.

[1bokke] 06/10/2017 10:38

Any companies using fructose as a sweetener may want to talk to Opti if the story is correct...On another note I have found a much better way to achieve quick weight loss than Go Figure, just got out of hospital having contracted sepsis and lost 2 stone in 12 days. It's not as pleasent as Go Figure but damn it works!! It's great to see the positive things that have been happening with Opti whilst I've been otherwise engaged. :-)

[someuwin] 06/10/2017 10:08

LPLDL®‏ @LPLDL1 · 3 minutes ago

Results suggest that the right bacteria in your gut could combat mental disorders including anxiety & depression...

[shrewdmole] 06/10/2017 09:47

MM not playing fair today.
Showing larger sells but not the buys.

A 40k+ buy should show at some point at 73.3p.

S

[judijudi] 06/10/2017 09:45

I don’t play the tick game myself
Think it’s rather silly
If I like a post I will say so
Likewise the reverse

[diamond fibre] 06/10/2017 09:15

I find it strange that I got a thumbs down (jj?) that I had returned from a family holiday and with out upsetting other posters said I had maxed out my shares (a buy hint) looks like the information I gained has come good, as they say the proof of the pudding is in the eating, I am already retired so all my shares are for the grandchildren. DIAMOND.

[devonlad] 06/10/2017 08:05

Do you like it Dorset, buy and hold for a good few years might make you a lot, not that you need it mind!

[2350220] 06/10/2017 07:57

Thanks for the translation Elrico,
John

[lufc5] 06/10/2017 00:49

Looks like a turning point. From an R&D, into a very nice com' business. I believe, that within circa 12-18 months, this will be around the £2 mark. I'm not always wrong.
Good luck long term holders. x

[dorset64] 05/10/2017 22:53

Would agree some great posts over the past couple of days.

[joyjoy13] 05/10/2017 22:28

This forum attracting night owls!
Chuckle....

What we like!

[joyjoy13] 05/10/2017 22:26

Oh my Goodness!
Mind blowing...

Thank you to the posters for the time consuming research you do and share on this board!
You truly deserve to be millionaires!

Never in all my years witnessed the level of communication shared here, this is truly a remarkable forum!

[elrico] 05/10/2017 22:17

John - google translate ;)

New company Yifu Health and British OptiBiotix Health signed a strategic cooperation agreement

Asia's first spiritual probiotic PS128 into Europe, high-pressure high society for the prevention of medical market

New News Integration Communications Department
In this month, we signed a strategic cooperation agreement with OptiBiotix Health, a UK-listed company, to transfer technology from the psychic probiotic PS128 from Taiwan's Yangming University to the European market. At present, we have locked the high-end preventive medicine pathways, Specifically for melancholy, insomnia, Parkinson's disease and autistic design of exclusive formula products. Yifu Health Medical also acquired OptiBiotix Health's cholesterol-specific strain LP-LDL's Asian agent. The two sides interactive strategy authorization, can quickly get through the Eurasian probiotic health care market. International industrial scale new milestone in Taiwan's probiotic benefits Fussa Medical Branch, Ministry of Economic circles special project: "to brain-gut axis basis of probiotic research and development," the outcome of the spin-off company, its innovative R & D results, "the spirit of probiotics PS128" is At present the world's only confirmed to regulate the brain dopamine concentration of the strains, depression, anxiety, irritability, autism and other symptoms with soothing effect. Has been included, including the EU 14 countries, Taiwan, Japan patents, and has entered the human clinical.

Yifu Health Health CEO Zheng Shengde said that in the past the global probiotic market is in Europe, Japan as the leading group, from Taiwan PS128 spirit probiotics in the development stage of attention, since January 2016 published in Brain Research, Widely regarded by the international scientific community, has been invited more than ten times at the international seminar. At the end of 2016, OptiBiotix took the initiative to express interest in the PS128 at the International Medical Association. For the sake of prudence, the two sides had cooperated for more than six months until the last month to finalize the specific direction of cooperation and set an important milestone for the internationalization of the probiotics industry in Taiwan. The British biotechnology companies rely on Taiwan's R & D strength to lock the high-end preventive medicine market

British OptiBiotix Health Plc (AIM: OPTI) was originally focused on obesity, high cholesterol and diabetes-related preventive medicine market, this and Yifu Health Medical signed the cross-licensing strain LP-LDL will be metabolized specific strains. "The target market for PS128 probiotics covers anxiety, depression, autism and Parkinson's disease," said Dr. Stephen O'Hara, CEO of OptiBiotix, who has a wealthy experience in the health industry. Research and development and market potential; the introduction of spiritual probiotics, but also on behalf of OptiBiotix to be able to break into the emerging areas of spiritual probiotics and new markets. Cooperation with Taiwan news published in the London market after the market has received a number of health care providers and investors Take the initiative to ask, the future process is quite exciting! " For technical time advantage and competition in Europe and the United States manufacturers Taiwanese production in Europe, Europe, the sale of

Asian probiotics expert Professor Cai Yingjie pointed out that 2018-2020 the main battlefield of international probiotics will fall on the spirit Psychological and neurodegenerative diseases of the functional strains of research and development, Taiwan's technology is still in the leading group. Yi Fu students from the beginning that is focused on the development of the most advanced mental probiotics, jump low-tech threshold of the Red Sea market, directly into the latest mental and psychological areas; product development strategy cut by the food, but to strengthen clinical research and mechanism research, The ultimate goal, with the European and American manufacturers racing.

In order to break through the international trade barriers of probiotics, Yi Fu students more efforts to pull the strain production line to Europe, and Italy Milan veteran probiotics factory Sacco Srl signed an agreement, package production PS128 powder, in the production, For production and order time advantage. Synergy agent metabolic probiotics LP-LDL

Yifu Health Health The cooperation with OptiBiotix also includes the Asian agent for metabolic probiotics LP-LDL. Scientific data show that LP-LDL can effectively reduce cholesterol, triglycerides, and with Jewish, halal, and pharmaceutical grade fermentation and preparation plant certification, the future will be developed into the weight loss of three higher related health care products.

Professor JIA Ying-jie, a professor of Asian probiotics, added that probiotic research and development has entered a fairly mature era of specialized strains. The first generation of probiotics is the most widely known "intestinal health function", and the second generation is "immunomodulation Function ", the third generation is" metabolic regulation "such as L-PLDL and Taiwan native K21 strain, and the fourth generation is the regulation of neuropsychological functions, such as PS128. The new blood introduced in this international cooperation, in the future product development has great potential.